

## PRESS RELEASE

### **ASC Biosciences, Inc. adds new Intellectual Property to its IP Portfolio**

PALM DESERT, CA, MAY 17, 2018 – ASC Biosciences, Inc. ("ASC") symbol ASCW, is pleased to announce that its License Agreement with New York Medical College (the "College") has been enhanced to include new intellectual property to its existing licensed portfolio.

A new patent application was recently filed by the College, entitled:

#### **Transcriptive Analysis of adult MSC's and Multipotent Adult Stem Cells (MASCs) using RNA-SEQ.**

This patent application was filed pursuant to the continued research of Paul Lucas, Ph.D., Associate Professor of Orthopedic Surgery, and inventor of MASCs. This patent provides gene expression identification of MASCs and the ability of human MASCs to regenerate tissues.

ASC, as the Licensee of MASCs, looks forward to the expeditious approval of this patent by the US Patent and Trademark Office which will ensure ASC remains the frontrunner in the market for truly regenerative orthopedic and aesthetic stem cell therapies for many years to come.

In light of several inter-species experiments using the patented human allogenic MASCs, ASC will, in the coming months, embark on a limited program of pre-clinical human trials in an offshore location. The accumulated database of successful therapies, proving the efficacy of MASCs in generating new tissue in humans, will enable ASC to initiate preliminary discussions with the FDA with regard to commencing FDA approved clinical trials in the United States.

## **About ASC Biosciences, Inc.**

ASC Biosciences, Inc. ("ASC" or the "Company") is a development stage biotechnology company that has a proprietary adult stem cell platform capable of forming nearly every tissue in the human body. These cells, Multipotent Adult Stem Cells ("MASCs"), will differentiate into cartilage, bone, tendon, muscle, ligament, fat, blood vessels, nerves, skin, etc. in humans. MASCs have apparent unlimited proliferation potential (do not reach replicative senescence) and have been shown to regenerate tissues by differentiating into the cell types at the site. MASCs lack the ability to cause a rejection response and can thus be used allogeneically - which means that cells harvested from a single donor can be expanded in culture and the expanded cells can be used to treat hundreds, thousands, or millions of patients. ASC believes it has a sustainable competitive advantage with its MASCs. Once FDA approved, the Company's MASCs will replace the need to use autologous stem cells for therapies. The MASCs will essentially become known as "cells in a bottle", providing a specified dose of adult stem cells for specific therapies, which is an enormous advantage over harvesting cells from a patient's body. ASC intends to establish an intellectual property portfolio that will provide proprietary dominion in the repair and regeneration of all human tissues. For more information visit: <http://www.ascbio.com> or @ASCbio1 on Facebook.

## **Forward-Looking Statements**

*Certain statements contained herein constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current expectations, estimates and projections about ASC Biosciences, Inc. industry, management's beliefs and certain assumptions made by management. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Because such statements involve risks and uncertainties, the actual results and performance of the Company may differ materially from the results expressed or implied by such forward-looking statements. Given these uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. Unless otherwise required by law, the Company also disclaims any obligation to update its view of any such risks or uncertainties or to announce publicly the result of any revisions to the forward-looking statements made here. Readers should review carefully reports or documents the Company files periodically with the*

<https://www.otcmarkets.com>. Contact: ASC Biosciences, Inc. Neville Pearson,  
President/Chief Executive Officer [Neville@ascbio.com](mailto:Neville@ascbio.com) or [knowledge@ascbio.com](mailto:knowledge@ascbio.com).